RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

Inclusion Criteria: * Diagnosed with AML according to the 2022 WHO diagnostic criteria; * Age 60-75 years; * Intermediate to high-risk AML according to the ELN criteria, AML with myelodysplasia-related changes (AML-MRC) or therapy-related AML (t-AML), or core-binding factor AML (CBF-AML) with D816 KIT mutation; or newly diagnosed hypercellular leukemia (WBC ≥ 10×10\^9/L); * Achieved CR or CR with incomplete hematologic recovery (CRi) after one to two courses of induction chemotherapy; * Have a matched related, haploidentical, or mismatched unrelated hematopoietic stem cell donor; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; Creatinine clearance ≥ 60 mL/min (calculated using the Cockcroft-Gault formula); * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3× the upper limit of normal (ULN), and total bilirubin ≤ 2× ULN; * Echocardiography (ECHO) showing left ventricular ejection fraction (LVEF) ≥ 50%; Expected survival \> 8 weeks; * Voluntarily signed the informed consent form and can understand and comply with the study's requirements. Exclusion Criteria: * Currently has clinically active cardiovascular disease, such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any class 3 or 4 heart disease according to the New York Heart Association (NYHA) functional classification, or a history of myocardial infarction within 3 months before screening; * Other severe diseases that may limit the patient's participation in this trial (e.g., severe infection, renal failure); * Known human immunodeficiency virus (HIV) infection or severe viral hepatitis not controlled by medication; * Pregnant or breastfeeding women; * Unable to understand, comply with the study protocol, or unable to sign the informed consent form.